Dissolution

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Volumn , Issue , 2008, Pages 483-544

  Tiwary, A K ^a   Sapra, Bharti ^a   Jain, Subheet ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Coprocessed lactose; Dicalcium phosphate; Directly compressible vehicles

Indexed keywords

EID: 85052179399     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch15     Document Type: Chapter

References (234)

1. Czeisler JL, Perlman KP. Encyclopedia of Pharmaceutical Technology, Volume 4. New York:Marcel Dekker; 1991, pp 40-52.
2. Scolk KGV, Zogiio M, Carstensen JT. Pharmaceutical Dosage Forms:Tablets, Volume I. New York:Marcel Dekker; 1980, pp 73-105.
3. Shah MA, Wilson RG. Some effects of humidity and heat on the tableting properties of microcrystalline cellulose formulations. I. J Pharm Sci 1968;57:181-182.
4. Brownley CA, Lachman L. Browning of spray-processed lactose. J Pharm Sci 1964;53:452-454.
5. Van Kamp HV, Bolhuis GK, Kussendrager KD, Lerk CF. Studies on tableting properties of lactose. IV. Dissolution and disintegration properties of different types of crystalline lactose. Int J Pharm 1986;28:229-238.
6. Shangraw RF. Direct compression tableting. In Encyclopedia of Pharmaceutical Technology , Volume 4 2nd ed. New York:Marcel Dekker; 1980, pp 85-160.
7. Lerk CF. Consolidation and compaction of lactose. Drug Dev Ind Pharm 1993;19:2359-2398.
8. Roberts RJ, Rowe RC. Effect of punch velocity on the compaction of a variety of materials. J Pharm Pharmacol 1985;37:377-384.
9. Fell JT, Newton JM. The tensile strength of tablets. J Pharm Sci 1968;20:657-658.
10. Gohel MC, Patel LD, Amin AF, Jogani PD, Bajaj SB, Patel GJ. Studies in improvement of flow and compressional characteristics of lactose. Int J Pharm Excipients 1999;1:86-92.
11. Gohel MC, Jogani PD. Functionality testing of a multifunctional directly compressible adjuvant containing lactose, polyvinyl pyrrolidone, and croscarmellose sodium. Pharm Technol 2002;25:64-82.
12. Wong DY, Wright P, Aulton ME. Deformation of alpha-lactose monohydrate and anhydrous alpha-lactose monocrystals. Drug Dev Ind Pharm 1988;14:2109-2126.
13. Shukla AJ, Price JC. Effect of moisture content on compression properties of directly compressible high beta-content anhydrous lactose. Drug Dev Ind Pharm 1991;17:2067-2081.
14. Alpar O, Hersey JA, Shotton E. The compression properties of lactose. J Pharm Pharmacol 1970;22:1S-7S.
15. Bolhuis GK, Lerk CF. Comparative evaluation of excipients for direct compression. Part 1. Pharma Weekb 1973;108:469-481.
16. Vromans H, Bolhuis GK, Lerk CF, Kussendrager KD. Studies on tableting properties of lactose. VIII. The effect of variations in primary particle size, percentage of amorphous lactose and addition of a disintegrant on the disintegration of spray-dried lactose tablets. Int J Pharm 1987;39:201-206.
17. Bolhuis GK, Zuurman K. Tableting properties of experimental and commercially available lactose granulations for direct compression. Drug Dev Ind Pharm 1995;21:2057-2071.
18. Bavitz JF, Schwartz JB. Direct compression vehicles, part II. Drug Cosmetic Ind 1976;118(4):60-77.
19. Hwang R, Peck GR. A systematic evaluation of the compression and tablets characteristics of various types of microcrystalline cellulose. Pharm Technol 2001;24:112-132.
20. Obae K, Iijima H, Imada K. Morphological effect of microcrystalline cellulose particles on tablet tensile strength. Int J Pharm 1999;182:155-164.
21. Lahdenpaa E, Niskanen M, Yliruusi J. Crushing strength, disintegration time and weight variation of tablets compressed from three Avicel pH grades and their mixtures. Eur J Pharm Biopharm 1997;43:315-322.
22. Reus-Medina M, Lanz M, Kumar V, Leuenberger H. Comparative evaluation of the powder properties and compression behaviour of a new cellulose based direct compression excipient and Avicel PH 102. J Pharm Pharmacol 2004;56:951-956.
23. Bolhuis GK, Chowhan ZT. Materials for direct Compression, Pharmaceutical Powder Compaction Technology, Volume 7. New York:Marcel Dekker; 1996, pp 419-499.
24. Shangraw RF. Direct compression tableting. In Encyclopedia of Pharmaceutical Technology , Volume 4, 2nd ed. New York:Marcel Dekker; 1988, pp 85-160.
25. Rizzuto AB, Chen AC, Veiga ME. Modification of the sucrose crystal structure to enhance pharmaceutical properties of excipient and drug substances. Pharm Technol 1984;8:32-39.
26. Olmo IG, Ghaly ES. Evaluation of two dextrose-based directly compressible excipients. Drug Dev Ind Pharm 1998;24:771-778.
27. Papadimitriou E, Efentakis M, Choulis NH. Evaluation of maltodextrins as excipients for direct compression and tablets and their influence on the rate of dissolution. Int J Pharm 1992;86:131-136.
28. Levy G. Effect of certain tablet formulation factors on dissolution rate of the active ingredient I. J Pharm Sci 1963;52:1039-1046.
29. Manudhane KS, Contractor AM, Kim HY, Shangraw RF. Tableting properties of a directly compressible starch. J Pharm Sci 1969;61:616-620.
30. Underwood TW, Cadwallader DE. Influence of various starches on dissolution rate of salicylic acid from tablets. Pharm Sci 1972;58:239-243.
31. Hsu SH, Tsai TR, Chuo WH, Cham TM. Evaluation of era-tab as direct compression excipients. Drug Dev Ind Pharm 1997;23:711-716.
32. Heinze F. Starch-the natural excipient choice. Manufacturing Chemist 2002;73:40-42.
33. Rees JE, Rue PJ. Time dependent deformation of some direct compression excipients. J Pharm 1978;30:601-607.
34. Khan KA, Rhodes, CT. Effect of variation in compaction force on properties of six direct compression tablet formulation. J Pharm Sci 1976;65:1835-1837.
35. Gohel MC. A review of co-processed directly compressible excipients. J Pharm Pharm Sci 2005;8:76-93.
36. Whiteman M, Yarwood RJ. Evaluation of six lactose-based materials as direct compression tablet excipients. Drug Dev Ind Pharm 1988;14:1023-1040.
37. Plaizier-Vercammen JA, Van Den Bossche H. Evaluation of the tableting properties of a new excipient for direct compression. Drugs Made in Germany 1993;36:133-137.
38. Schmidt PC, Rubensdorfer CJ. Evaluation of ludipress as a multipurpose excipient for direct compression. Part 1. Powder characteristics and tableting properties. Drug Dev Ind Pharm 1994;20:2899-2925.
39. Schmidt PC, Rubensdorfer CJ. Evaluation of ludipress as a multipurpose excipient for direct compression. Part II:Inactive blending and tableting with micronized glibenclamide. Drug Dev Ind Pharm 1994;20:2927-2952.
40. Garr JS, Rubinstein MH. Compaction properties of a cellulose-lactose direct compression excipient. Pharm Tech Int 1991;3:24-27.
41. Armstrong NA, Roscheisen G, Al-Aghbar MR. Cellactose as a tablet diluent. Manufacturing Chemist 1996;67:25-26.
42. Reimerdes D. The near future of tablet excipients. Manufacturing Chemist 1993;64:14-15.
43. Belda PM, Mielck JB. The tabletting behaviour of cellactose compared with mixtures of celluloses with lactoses. Eur J Pharm Biopharm 1996;42:325-330.
44. Casalderrey M, Souto C, Concheiro A, Gomea-Amoza JL, Martinez-Pacheco RA. Comparison of cellactose with two ad hoc processed lactose-cellulose blends as direct compression excipients. Chem Pharm Bull 2000;48:458-463.
45. Gohel MC, Modi CJ, Jogani PD. Functionality testing of a coprocessed diluent containing lactose and microcrystalline cellulose. Pharm Technol 1999;22:40-46.
46. Gohel MC, Bariya S, Jogani PD. Investigation in direct compression characteristics of coprocessed adjuvant containing lactose, microcrystalline cellulose and dicalcium phosphate. Pharm Dev Technol 2003;8:143-152.
47. Meggle AG. Technical information at www.megglepharma.de/en/product/uebersich/ starlac.
48. Hauschild K, Picker KM. Evaluation of new coprocessed compound based on lactose and maize starch for tablet formulation. AAPS PharmSci 2004;6:1-12.
49. Tsai T, Wu J, Ho H, Sheu M. Modification of physical characteristics of microcrystalline cellulose by codrying with β-cyclodextrin. J Pharm Sci 1998;87:117-122.
50. Levis SR, Deasy PB. Pharmaceutical applications of size reduced grades of surfactant co-processed microcrystalline cellulose. Int J Pharm 2001;230:25-33.
51. Ishikawa T, Mukai B, Shiraishi S, Utoguchi N, Fujii M, Matsumoto M, Watanaba Y. Preparation of rapidly disintegrating tablet using new types of microcrystalline cellulose (PH-M Series) and low substituted-hydroxypropylcellulose or spherical sugar granules by direct compression method. Chem Pharm Bull 2001;49:134-139.
52. Lourdes Garzo'n M, Villafuerte L. Compactibility of mixtures of calcium carbonate and microcrystalline cellulose. Int J Pharm 2002;231:33-41.
53. Luukkonen P, Schaefer T, Hellen L, Juppo AM, Yliruusi J. Rheological characterization of microcrystalline cellulose and silicified microcrystalline cellulose wet masses using a mixer torque rheometer. Int J Pharm 1999;188:181-192.
54. Allen JD. Improving DC with SMCC. Manufacturing Chemist 1996:67:19-23.
55. Kachimanis K, Nikolakakis I, Malamataris S. Tensile strength and disintegration of tableted silicified microcrystalline cellulose:influences of interparticle bonding. J Pharm Sci 2003;92:1489-1501.
56. Wei S. Preparation and physical/mechanical evaluation of new crystallinity forms of cellulose as pharmaceutical excipients. Minneapolis, MN:University of Minnesota; 1991.
57. Banker GS, Wei S. Low crystallinity cellulose. U.S. patent 5417984. 23 May 1995.
58. Wei S, Kumar V, Banker GS. Phosphoric acid mediated depolymerization and decrystallinization of cellulose. Preparation of low crystallinity cellulose-a new pharmaceutical excipient. Int J Pharm 1996;142:175-191.
59. Kumar V, Kothari SH, Banker GS. Effect of agitation rate on the generation of low crystallinity cellulose from phosphoric acid. J Appl Polym Sci 2001;82:2624-2628.
60. Jones TM. Symposium On Powders. Dublin:Society of Cosmetic Chemists of Great Britain; 1969.
61. Peleg M, Mannheim CH. Effect of conditioners on the flow properties of powdered sucrose. Powder Technol 1973;7:45-50.
62. Matsuda Y, Minamida Y, Hayashi S. Comparative evaluation of tablet lubricants:effect of application method on tablet hardness and ejectability after compression. J Pharm Sci 1976;65:1155-1160.
63. Iranlove TA, Parrot EL. Effects of compression force, particle size, and lubricants on dissolution rate. J Pharm Sci 1978;67:535-539.
64. Chowhan ZT, Chi LH. Drug-excipient interactions resulting from powder mixing. IV:Role of lubricants and their effect on in vitro dissolution. J Pharm Sci 1986;75:542-545.
65. Westerberg M, Nystrom C. Physicochemical aspects of drug release. XII. The effect of some carrier particle properties and lubricant admixture on drug dissolution from tableted ordered mixtures. Int J Pharm 1991;69:129-141.
66. Ong JTH, Chowhan ZT, Samuels JG. Drug-excipient interactions resulting from powder mixing. VI. Role of various surfactants. Int J Pharm 1993;96:231-242.
67. Desai DS, Rubitski BA, Varia SA, Newman AW. Physical interactions of magnesium stearate with starch derived disintegrants and their effects on capsule and tablet dissolution. Int J Pharm 1993;91:217-226.
68. Desai DS, Rubitski BA, Bergum JS, Varia SA. Effect of various fomulation factors on dissolution stability of aztreonam, hydrochlorothiazide, and sorivudine capsules. Drug Dev Ind Pharm 1994;110:249-255.
69. Shah AC, Mlodozeniec AR. Mechanism of surface lubrication:influence of duration of lubricant excipient mixing on processing characteristics of powders and properties of compressed tablets. J Pharm Sci 1997;66:1377-1382.
70. Chowhan ZT, Chi LH. Drug-excipient interactions resulting from powder mixing. V:Role of sodium lauryl sulphate. Int J Pharm 1986;60:61-78.
71. Otsuka M, Gao J, Matsuda Y. Effects of mixer and mixing time on the pharmaceutical properties of theophylline tablets containing various kinds of lactose as diluents. Drug Dev Ind Pharm 1993;19:333-348.
72. Kikuta J, Kitamori N. Effect of mixing time on the lubricating properties of magnesium stearate and the final characteristics of the compressed tablet. Drug Dev Ind Pharm 1994;20:343-355.
73. Otsuka M, Sato M, Matsuda Y. Comparative evaluation of tableting compression behaviours by methods of internal and external lubricant addition:inhibition of enzymatic activity of trypsin preparation by using external lubricant addition during the tableting compression process. AAPS PharmSci 2001;3:1-11.
74. Khan KA, Rooke DJ. Effect of disintegrant type upon the relationship between compressional pressure and dissolution efficiency. J Pharm Pharmacol 1976;28:633-636.
75. Zhang Y, Law Y, Chakrabarti S. Physical properties and compact analysis of commonly used direct compression binders. AAPS PharmSci 2003;4(article 62):1-11.
76. Proost JH, Bolhuis GK, Lerk CF. The effect of the selling capacity of disintegrants on the in vitro and in vivo availability of diazepam tablets, containing magnesium stearate as a lubricant. Int J Pharm 1983;13:287-296.
77. Sjokvist E, Nystrom C, Alden M. Physicochemical aspects of drug release. IX:Investigation of some factors that impair dissolution of drugs from solid particulate dispersion systems. Int J Pharm 1989;54:161-170.
78. Johnson JR, Wang LH, Gordon MS, Chowhan ZT. Effect of formulation solubility and hygroscopicity on disintegrant efficiency in tablets prepared by wet granulation, in terms of dissolution. J Pharm Sci 1991;80:469-471.
79. Gordan MS, Rudrarju VS, Rhie JK, Chowhan ZT. The effect of aging on the dissolution of wet granulated tablets containing super disintegrants. Int J Pharm 1993;97:119-131.
80. Bolhuis GK, Zuurman K, Wierik GHP. Improvement of dissolution of poorly soluble drugs by solid deposition on a super disintegrant. II. The choice of super disintegrants and effect of granulation. Eur J Pharm BioPharm 1997;5:63-69.
81. Lundqvist AEK, Podczeck F, Newton JM. Influence of disintegrant type and proportion on the properties of tablets produced from mixtures of pellets. Int J Pharm 1997;147:95-107.
82. Chen CR, Cho SL, Lin CK, Lin YH, Chiang ST, Wu HL. Dissolution difference between acidic and neutral media of acetaminophen tablets containing a super disintegrant and a soluble excipient. II. Chem Pharm Bull 1998;46:478-481.
83. Sallam E, Ibrahim H, Dahab RA, Shubair M, Khalil E. Evaluation of fast disintegrants in terfenadine tablets containing a gas evolving disintegrant. Drug Dev Ind Pharm 1998;24:501-507.
84. Carmella C, Colombo P, Conte U, La Manna A. Tablet disintegrate update;the dynamic approach. Drug Dev Ind Pharm 1987;13:2111-2145.
85. Lopez-Solis J, Villafuerte-Robles L. Effect of disintegrants with different hygroscopicity on dissolution of Norfloxacin/Pharmatose DCL 11 tablets. Int J Pharm 2001;216:127-135.
86. Zao N, Augsburger LL. The influence of swelling capacity of superdisintegrants in different pH media on the dissolution of hydrochlorothiazide from directly compressed tablets. AAPS PharmSci 2005;6:E120-E126.
87. Zao N, Augsburger LL. Functionality comparison of 3 classes of superdisintegrants in promoting aspirin tablet disintegration and dissolution. AAPS PharmSci 2005;6:E634-E640.
88. Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. Time-and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol 2004;10:1769-1774.
89. Wakerly Z, Fell JT, Attwood D, Parkins D. Pectin/ethylcellulose film coating formulations for colonic drug delivery. Pharm Res 1996;13:1210-1212.
90. Prabakaran D, Singh P, Kanaujia P, Mishra V, Jaganathan KS, Vyas SP. Controlled porosity osmotic pumps of highly aqueous soluble drug containing hydrophilic polymers as release retardants. Pharm Dev Technol 2004;9:435-442.
91. Rao VM, Haslam JL, Stella VJ. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE) (7m)-beta-cyclodextrin as a solubilizing agent. J Pharm Sci 2001;90:807-817.
92. Tiwari D, Sause R, Madan PL. Evaluation of polyxyethylene homopolymers for buccal bioadhesive drug delivery device formulations. AAPS PharmSci 1999;1(article 13):1-8.
93. Chiao CS, Price JC. Formulation, preparation and dissolution characteristics of propranolol hydrochloride microspheres. J Microencapsulation 1994;11:153-159.
94. Saravanan M, Natraj KS, Ganesh KS. Hydroxypropyl methylcellulose based cephalexin extended release tablets:influence of tablet formulation, hardness and storage on in vitro release kinetics. Chem Pharm Bull 2003;51:978-983.
95. Bordaweka MS, Zia H. Evaluation of polyvinyl acetate dispersion as a sustained release polymer for tablets. Drug Deliv 2006;13:121-131.
96. Bravo SA, Lamas MC, Salomon CJ. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices. J Pharm Pharm Sci 2002;5:213-219.
97. Pignatello R, Ferro M, Puglisi G. Preparation of solid dispersions of nonsteroidal anti-inflammatory drugs with acrylic polymers and studies on mechanisms of drug-polymer interactions. AAPS PharmSci 2002;3(article 10):1-11.
98. Adeyeye MC, Mwangi E, Katondo B, Jain A, Ichikawa H, Fukumori Y. Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process:I. Eudragit-based formulation and possible drug-excipient interaction. J Microencapsulation 2005;22:333-342.
99. Jenquin MR, McGinity JW. Characterization of acrylic resin matrix films and mechanisms of drug-polymer interactions. Int J Pharm 10:23-34.
100. Karlsen J. Excipient properties of chitosan. Manufacturing Chemist 1991;62:18-19.
101. Nunthanid J, Laungtana-anan M, Sriamornsak P, Limmatvapirat S, Puttipipatkhachorn S, Lim, LY, Khor E. Characterization of chitosan acetate as a binder for sustained release tablets. J Control Release 2004;99:15-26.
102. Gao P, Nixon P, Skoug J. Diffusion in HPMC gels. II. Prediction of drug release rates from hydrophilic matrix extended-release dosage forms. Pharm Res 1995;12:965-971.
103. Phaechamud T, Koizumi T, Ritthidej GC. Chitosan citrate as film former:compatibility with water-soluble anionic dyes and drug dissolution from coated tablets. Int J Pharm 2000;198:97-111.
104. Ritthidej GC, Phaechamud TW. Effect of anionic water-soluble dyes on film coating properties of chitosan acetate. Drug Dev Ind Pharm 2003;29:585-594.
105. Breikkreutz J. Leakage of enteric (Eudragit L)-coated dosage forms in simulated gastric juice in the presence of poly(ethylene glycol). J Control Release 2000;67:79-88.
106. Mathur AV, Hammonds KF, Klier J, Scranton AB. Equilibrium swelling of poly(methacrylic acid-ethylene glycol) hydrogels:effect of swelling medium and synthesis conditions. J Control Release 1998;54:177-184.
107. Chasseaud LF, Taylor T. Bioavailability of drugs from formulations after oral administration. Annu Rev Pharmacol 1974;14:35-46.
108. Bourne DWA, Dittert LW. Modern Pharmaceutics 4th ed. New York:Marcel Dekker; 1996, pp 122-153.
109. Banakar UV, Makoid MC. Drug Development Process:Increasing Efficiency and Cost-Effectiveness. New York:Marcel Dekker Taylor & Francis CRC; 1996, pp 117-168.
110. Du J, Hoag SW. Characterization of excipient and tableting factors that influence folic acid dissolution, friability and breaking strength of oil-and water-soluble multi vitamin with minerals tablets. Drug Dev Ind Pharm 2003;29:1137-1147.
111. United States Pharmacopoia 24 and National Formulary 19. USP publishers. Rockville, MD:US Pharmacopoeia; 2001.
112. Urakami K, Shono Y, Higashi A, Umemoto K, Godo M. A novel method for estimation of transition temperature for polymorphic pairs in pharmaceuticals using heat of solution and solubility data. Chem Pharm Bull 2002;50:263-267.
113. Hancock BC, Parks M. What is the true solubility advantage of amorphous pharmaceuticals? Pharm Res 2001;17:397-404.
114. Bartolomei M, Bertocchi P, Antoniella E, Rodomonte A. Physicochemical charaterization and intrinsic dissolution study of new hydrate form of diclofenac sodium:comparison with anhydrous form. J Pharm Biomed Anal 2006;40:1105-1113.
115. Manca ML, Zaru M, Ennas G, Valenti D, Sininco C, Loy G, Fadda AM. Diclofenac-β-cyclodextrin binary system:physicochemical characterization and in vitro dissolution and diffusion study. AAPS PharmSci Tech 2005;6(article 58):E464-E472.
116. Mukne AP, Nagarsenker MS. Triamterene-β-cyclodextrin systems:preparation, characterization and in vivo evaluation. AAPS PharmSci Tech 2004;5(article 19):1-9.
117. Marlowe E, Shangraw RF. Dissolution of sodium salicylate from tablet matrices prepared by wet granulation and direct compression. J Pharm Sci 1967;56:498-504.
118. Abdou HM. Remington's Pharmaceutical Sciences, 17th ed. Easton, PA:Mack Publishing ; 1986, pp 653-666.
119. Bansal P, Haribhakti K, Subramanian V, Plakogiannis F. Effect of formulation and process variables on the dissolution profile of naproxen sodium from tablets. Drug Dev Ind Pharm 1994;20:2151-2156.
120. Mitchell K, Ford JL, Armstrong DJ, Elliott PNC, Hogan JE, Rostron C. The influence of the particle size of hydroxypropylmethylcellulose K15M on its hydration and performance in matrix tablets. Int J Pharm 1999;100:175-179.
121. Gao P, Meury RH. Swelling of hydroxypropyl methylcellulose matrix tablets. 1. Characterization of swelling using a novel optical imaging method. J Pharm Sci 1996;85:725-731.
122. Chowhan ZT, Yang IC. Effect of intergranular versus intragranular cornstarch on tablet friability and in vitro dissolution. J Pharm Sci 1983;72:983-988.
123. Zhang YE, Tchao R, Schwartz JB. Effect of processing methods and heat treatment on the formation of wax matrix tablets for sustained drug release. Pharm Dev Technology 2001;6:131-144.
124. Finholt P. In Leeson LJ, Carstenson JT, Eds. Dissolution Technology. Industrial Pharmaceuticals Technology Section. Washington DC:Apha; 1974, pp 136-137.
125. Ghorab MK, Adeyeye MC. Enhancement of ibuprofen dissolution via wet granulation with beta-cyclodextrin. Pharm Dev Technol 2001;6:305-304.
126. Al-Kassas RS, Gilligan CA, Po ALW. Processing factors affecting particle size and in vitro drug release of sustained release ibuprofen microspheres. Int J Pharm 1993;94:59-67.
127. Kanig JL, Rudnic EM. The mechanism of disintegrant action. Pharm Technol 1984;8:50-62.
128. Levy G, Gumtow RH. Effect of certain formulation factors on dissolution rate of the active ingredient III:tablet lubricants. J Pharm Sci 1963;52:1139-1144.
129. Basak SC, Sivakamasundari T, Shivagamasundari S, Manavalan R. Influence of granule size and lubricant concentration on the dissolution of paracetamol tablets. Indian J Pharm Sci 2003;65:299-301.
130. Lerk CF, Bolhuis GK, Smallenbroek AJ, Zuurman K. Interaction of tablet disintegrants and magnesium stearate during mixing II. Effect on dissolution rate. Pharm Acta Helv 1982;57:282-286.
131. Van Oudtshoorn MC, Potgieter FJ, de Blaey CJ, Polderman J. The influence of compression and formulation on the hardness, disintegration, dissolution, absorption and excretion of sulphadimidine tablets. J Pharm Pharmacol 1971;23:583-586.
132. Massimo G, Santi P, Colombo G, Nicoli S, Zani F, Colombo P, Bettini R. The suitability of disintegrating force kinetics for studying the effect of manufacturing parameters on spironolactone tablet properties. AAPS PharmSci 2003;4(article17):1-7.
133. Tuladhar MD, Carless JE, Summers MP. The effects of polymorphism, particle size and compression pressure on the dissolution rate of phenylbutazone tablets. J Pharm Pharmacol 1983;35:269-274.
134. Ganderton D, Hadgraft JW, Rispin WT, Thompson AG. The breakup and dissolution of phenindione tablets. Pharm Acta Helv 1967;42:152-162.
135. Kent JS. Implant pellets I:effects of compression pressure on in vivo dissolution of delmadinone acetate pellets. J Pharm Sci 1976;65:89-92.
136. Lin KH, Lin SY, Li MJ. Compression forces and amount of outer coating layer affecting the time-controlled disintegration of the compression-coated tablets prepared by direct compression with micronized ethylcellulose. J Pharm Sci 2001;90:2005-2009.
137. Food and Drug Administration. Guidance for Industry:Immediate release solid oral dosage forms;scale-up and postapproval changes:chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalance documentation. Rockville, MD:FDA Nov 1995.
138. Prabhu S, Jacknowitz AI, Stout PJ. A study of factors controlling dissolution kinetics of zinc complexed protein suspensions in various ionic species. Int J Pharm 2001;217:71-78.
139. Tang L, Khan SU, Muhammad NA. Evaluation and selection of biorelevant dissolution media for a poorly water soluble new chemical entity. Pharm Dev Technol 2001;6:531-540.
140. Noory C, Tran N, Ouderkirk L, Shah V. Steps for development of a dissolution test for sparingly water soluble drug products. Dissolution Technol 2000;Article 3:1-5.
141. British Pharmacopoeia. London:British Pharmacopoeia Commission Bernan Press; 2003.
142. Government of India Ministry of Health and Family Welfare. The Pharmacopoeia of India. Delhi, India:Controller of Publication; 1996.
143. Crison JR, Weiner ND, Amidon GL. Dissolution media for in vitro testing of water insoluble drugs:effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulphate. J Pharm Sci 1997;86:384-388.
144. Jinno J, Oh D, Crison JR, Amidon GL. Dissolution of ionizable water insoluble drugs:the combined effect of pH and surfactant. J Pharm Sci 2000;89:268-274.
145. TM ) in multi-pH media using United States Pharmacopeia apparatus II and III. AAPS Pharm-SciTech 2002;3 (article 33):1-9.
146. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998;15:698-705.
147. Crison JR. Developing dissolution test for modified release dosage form:general considerations. http://wwwdissolutiontechcom/Dtresour/299articlesCrison,htm.
148. Moller H, Wirbitzki E. Regulatory aspects of modified release dosage form:special cases of dissolution testing using the flow-through system. Bollettino Chim Farma 1993;132:105-115.
149. Burns SJ, Corness D, Hay G, Higginbottom S, Whelan I, Attwood D, Barnwell SG. Development and validation of an in vitro dissolution method for a floating dosage form with biphasic release characteristics. Int J Pharm 1995;121:37-44.
150. Crail DJ, Tunis A, Dansereau R. Is the use of a 200 ml vessel suitable for dissolution of low dose drug products? Int J Pharm 2004;269:203-209.
151. Yu LX, Carlin AS, Amidon GL, Hussain AS. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm 2004;270:221-227.
152. Banakar UV. Pharm Dissolution Testing. New York:Marcel Dekker; 1992, pp 107-187.
153. Sarapu A, Clark J. Elimination of tablet air entrapment using USP 1 rotating-basket dissolution apparatus. J Pharm Sci 1980;69:129.
154. Cappola ML. A better dissolution method for ranitidine tablets USP. Pharm Dev Technol 2001;6:11-17.
155. Hamlin WE, Nelson E, Ballard BE, Wagner JG. Loss of sensitivity in distinguishing real differences in dissolution rates due to increasing intensity of agitation. J Pharm Sci 1962;51:432-435.
156. Kukura J, Baxter JL, Muzzio FJ. Shear distribution and variability in the USP apparatus 2 under turbulent conditions. Int J Pharm 2004;279:9-17.
157. Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. In vitro dissolution profile of water insoluble drug dosage forms in the presence of surfactants. Pharm Res 1989;6:612-618.
158. Qureshi SA, Shabnam J. Cause of high variability in drug dissolution testing and its impact on setting tolerances. Eur J Pharm Sci 2001;12:271-276.
159. Wurster DE, Polli GP. Investigation of drug release from solids. V. Simultaneous influence of adsorption and viscosity on the dissolution rate. J Pharm Sci 1964;53:311-314.
160. Bodmeier R, Guo X, Sarabia RE, Skultety PF. The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions. Eudragit RS, RL 30D. Pharm Res 1996;13:52-56.
161. Fagan PG, Harrison PJ, Shankland N. A correlation between cloud point and disintegration of hydroxyalkylcellulose controlled release matrices. J Pharm Pharmacol 1989;41:25.
162. Jalil R, Ferdous AJ. Effect of viscosity increasing agent and electrolyte concentration on the release rate of theophylline from HPMC based sustained release capsules. Drug Dev Ind Pharm 1993;19:2637-2643.
163. Li WPA, Wong LP, Gilligan CA. Characterization of commercially available theophylline sustained or controlled-release systems:in vitro drug release profiles. Int J Pharm 1990;66:111-130.
164. Bonferoni MC, Rossi S, Ferrari F, Stavik F, Pena-Romero A, Caramella C. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes. AAPS PharmSciTech 2000;1(article 15):1-8.
165. Prasad VK, Rapaka RS, Knight PW, Cabana BE. Dissolution medium-a critical parameter to identify bioavailability problems of furosemide tablets. Int J Pharm 1982;11:81-90.
166. O'Hara TO, Dunne A, Butler J, Devane J. A review of methods used to compare dissolution profile data. AAPS PharmSciTech 2000;1(article 15):214-223.
167. Demirtürk E, Öner L. Evaluation of in vitro dissolution profile comparison methods of immediate release gliclazide tablet formulations. Hacettepe Univ J Faculty Pharm 2005;25:1-10.
168. Chow SC, Ki FYC. Statistical comparison between dissolution profiles of drug products. J BioPharm Stat 1997;7:241-258.
169. Qazi S, Samuel NKP, Venkatachalam TK, Uckun FM. Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. Int J Pharm 2003;252:27-39.
170. Tsong Y, Hammerstorm T, Sathe P, Shah VP. Statistical assessment of mean difference between two dissolution data sets. Drug Info J 1996;30:1105-1112.
171. Sathe P, Tsong Y, Shah VP. In vitro dissolution profilee comparison:statistics and analysis, model dependent approach. Pharm Res 1996;13:1799-1803.
172. 2. Pharm Res 1998;15:889-896.
173. Peh KK, Wong CF. Application of similarity factor in development of controlled release diltiazem tablet. Drug Dev Ind Pharm 2000;26:723-730.
174. Rescigno R. Bioequivalence. Pharm Res 1992;9:925-928.
175. Lin SY, Yang JC. In vitro dissolution behaviour of some sustained release theophylline dosage forms. Pharm Acta Helv 1989;4:236-240.
176. Sangali ME, Giunchedi P, Maggi L, Conte U, Gazzaniga A. Inert monolithic device with a central hole for constant drug release. Eur J Pharm Sci 1994;40:370-373.
177. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983;15:25-35.
178. Kim H, Fassihi R. Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. J Pharm Sci 1997;86:323-328.
179. El-Arini SK, Leuenberger H. Dissolution properties of praziquantel-PVP systems. Pharm Acta Helv 1998;73:89-94.
180. Crowder MJ. Keep timing the tablets:statistical analysis of pill dissolution rates. Appl Stat 1996;45:323-334.
181. Baker RW, Losdale HS. Controlled Release:Mechanisms and Rates. New York:Plenum Press, 1974, pp 15-71.
182. Jun HW, Lai JW. Preparation and in vitro dissolution tests of egg albumin microcapsules of nitrofurantoin. Int J Pharm 1983;16:65-77.
183. Shukla AJ, Price JC. Effect of drug (core) particle size on the dissolution of theophylline from microspheres made from low molecular weight cellulose acetate propionate. Pharm Res 1989;6:418-421.
184. Hopfenberg HB. In Paul DR, Harris FW. Eds. Controlled Release Polymeric Formulations. ACS Symposium Series 33. Washington DC:American Chemical Society; 1976, pp 26-31.
185. Higuchi T. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145-1149.
186. Desai SJ, Singh P, Simonelli AP, Higuschi WI. Investigation of factors influencing release of solid drug dispersed in inert matrices. III. Quantitative studies involving the polyethylene plastic matrix. J Pharm Sci 1966;55:1230-1234.
187. Desai SJ, Singh P, Simonelli AP, Higuschi WI. Investigation of factors influencing release of solid drug dispersed in inert matrices. IV. Some studies involving the polyvinyl chloride matrix. J Pharm Sci 1966;55:1235-1239.
188. Niebergall PJ, Milosovich G, Goyan JE. Dissolution rate studies. II. Dissolution of particles under conditions of rapid agitation. J Pharm Sci 1963;52:236-241.
189. Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharmacol 1972;24:979-981.
190. Pedersen PV, Myrick JW. Versatile kinetic approach to analysis of dissolution data. J Pharm Sci 1978;67:1450-1455.
191. Christensen FN, Hansen FY, Bechgaard H. Physical interpretation of parameters in the Rosin-Rammler-Sperling-Weibull distribution for drug release from controlled release dosage forms. J Pharm Pharmacol 1980;32:580-582.
192. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-133.
193. Varelas CG, Dixon DG, Steiner C. Zero order release from biphasic polymer hydrogels. J Control Release 1995;34:185-192.
194. Polli JE, Rekhi GS, Shah VP. Methods to compare dissolution profiles. Drug Info J 1996;30:1113-1120.
195. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY-S, Vastag KJ, Nishine JA. Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metab Dispos 1996;24:1111-1120.
196. Lin JH, Storey DE, Chen I-W, Xu X. Improved absorption of L-365, 260, a poorly soluble drug. Biopharm Drug Dispos 1996;17:1-16.
197. Yeleswara K, McLaughlin LG, Knipe JO, Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res 1997;22:45-51.
198. Clemens ET, Stevens CE. A comparison of gastrointestinal transit time in ten species of mammal. J Agric Sci 1980;94:735-737.
199. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 1995;16:351-380.
200. Obach RS, Baxter JG, Liston TE, Silber M, Jones BC, MACintyre F, Rance DJ, Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283:46-58.
201. Renkin EM, Gilmore JP. Handbook of Physiology-Renal Physiology. Baltimore, MD:Williams and Wilkins; 1973, pp 185-248.
202. Dressman JB, Yamada K. Pharmaceutical Bioequivalence. New York:Marcel Dekker; 1991, pp 235-266.
203. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093-1095.
204. Miyabayashi T, Morgan JP, Atitola MAO, Muhumuza L. Small intestinal emptying time in normal beagle dogs. A contrast radiographic study. Vet Radiol 1986;27:197-209.
205. Ilet KF, Tee LBG, Reeves PhT, Minchin RF. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990;46:67-93.
206. Degen LP, Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996;39:299-305.
207. Ikegami K, Tagawa K, Narisawa S, Osawa T. Suitability of the cynomolgus monkey as an animal model for drug absorption studies of oral dosage forms from the viewpoint of gastrointestinal physiology. Biol Pharm Bull 2003;1442-1447.
208. Kaniwa N, Aoyagi N, Ogata H, Ejima A. Gastric emptying rates of drug preparations. I. Effects of size of dosage form, food and species on gastric emptying rates. J PharmcobioDynam 1988;11:563-570.
209. Chiou1 WL, Buehler PW. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm Res 2002;19:868-873.
210. Edwards NA. Scaling of renal function in mammals. Comp Biochem Physiol 1975;52A:63-66.
211. Boxenbaum H. Interspecies variation in liver weight, hepatic blood flow, and antipyrin intrinsic clearance in extrapolation of benzodiazepines and phenytoin. J Phamacokinet Biopharm 1980;8:165-176.
212. Stahl WR. Scaling of respiratory variable in mammals. J Appl Physiol 1969;22:453-460.
213. m values for the metabolism of isofenphos by P-450 liver enzymes in animals and human. Toxicol Appl Pharmacol 1993;120:106-113.
214. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 1995;23:1231-1241.
215. Chauret N, Gauthier A, Martin J, Nicoll-Griffith D. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Rev 1997;25:1130-1136.
216. Shimida T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 1997;71:401-408.
217. Igarashi T, Tomihari N, Ohmori S, Ueno K, Kitagawa H, Satoh T. Comparison of glutathione S-transferase in mouse, guinea pig, rabbit and hamster liver cytosol to those in rat liver. Biochem Int 1986;13:641-648.
218. Stevens JC, Shipley LA, Cashman JR, Vandenbranden M, Wrighton SA. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metab Rev 1993;21:753-759.
219. Puri S, Kohli KK. Differences in hepatic drug metabolizing enzymes and their response to lindane in rat, rabbit and monkey. Pharmacol Toxicol 1995;77:136-141.
220. Kobayashi S, Murray S, Watson D, Sesardic D, Davies DS, Boobies AB. The specificity of inhibition of debrisoquine 4-hydroxylase activity in quinidine and quinine in rat is the reverse of that in man. Biochem Pharmacol 1989;38:2795-2799.
221. Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995;17:221-223.
222. Guidance for Industry. Extended release oral dosage forms:development, evaluation and application of in vitro/in vivo correlations. Washington DC:Food and Drug Administration CDER;Sept 1997.
223. Young D, Davane JG, Butler J. In Vitro-In Vivo Correlations. New York:Plenum Press; 1997.
224. Nelson E. Comparative dissolution rates of weak acid and their sodium salts. J Am Pharm Assoc 1958;47:297-300.
225. Schirmer RE, Kleber JW, Black HR. Correlation of dissolution, disintegration and bioavailability of aminosalicylic acid tablets. J Pharm Sci 1973;62:1270-1274.
226. Needham TE, Shah K, Kotzan J, Zia H. Correlation of aspirin excretion with parameter from different dissolution methods. J Pharm Sci 1978;67:1070-1073.
227. Fairweather WR. Investigating relationships between in vivo and in vitro pharmacological variables for the purpose of prediction. J Pharmacokinet BioPharm 1977;5:405-418.
228. Concherio A, Vila-Jato JL, Martinez-Pacheco R, Seijo B, Ramos T. In vitro-in vivo correlations of eight nitrofurantoin tablet formulations:effect of various technological factors. Drug Dev Ind Pharm 1987;13:501-516.
229. Wagner JG. Pharmacokinetics for the Pharmceutical Scientist. New York:Technomic Publishing; 1993, pp 259-269.
230. Bennett CA, Franklin NL. Statistical Analysis in Chemistry and the Chemical Industry. Hoboken, NJ:Wiley; 1963.
231. Johnson NL, Leone FC. Statistics and Experimental Design in Engineering and the Physical Sciences. Hoboken, NJ:Wiley; 1977.
232. Dressman J, Krämer J. Pharmaceutical Dissolution Testing. New York:Taylor & Francis Group; 2005.
233. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalance studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Washington DC:Food and Drug Administration CDER, Aug 2000.
234. Burgess DJ, Hussain AS, Ingallinera TS, Chen ML. Assuring quality and performance of sustained and controlled release parenterals:workshop report. AAPS PharmSci 2002;4(article 7):1-11.